Comparison of perioperative outcomes among non-small cell lung cancer patients with neoadjuvant immune checkpoint inhibitor plus chemotherapy, EGFR-TKI, and chemotherapy alone: a real-world evidence study

BACKGROUND: The utilization of neoadjuvant immune checkpoint inhibitor (ICI) plus chemotherapy has increased significantly for resectable non-small cell lung cancer (NSCLC). It is still unclear whether such a treatment paradigm affects perioperative outcomes compared with other neoadjuvant treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Deping, Xu, Long, Wu, Junqi, She, Yunlang, Su, Hang, Hou, Likun, E, Haoran, Zhang, Lei, Grossi, Francesco, Subramanian, Melanie P., Kim, Anthony W., Zhu, Yuming, Chen, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359956/
https://www.ncbi.nlm.nih.gov/pubmed/35958337
http://dx.doi.org/10.21037/tlcr-22-476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359956/
https://www.ncbi.nlm.nih.gov/pubmed/35958337
http://dx.doi.org/10.21037/tlcr-22-476

Ejemplares similares